SSTR2 and Hypoglycemia: Although the difference was not significant, the T2D-SSTR2 antagonist-treated animals had a higher nadir glucose (4.1 ± 1.2 mmol/L), slightly above the hypoglycemia threshold of 3.9 mmol/L, as compared to the T2D vehicle group where the average was below the hypoglycemic threshold (3.5 ± 0.6 mmol/L) (p = 0.07) (Figure 4A inset).